Exhibit 10.3

[***] INDICATES MATERIAL THAT  HAS   BEEN   {E2 OMITTED}  AND FOR WHICH CONFIDENTIAL TREATMENT  HAS   BEEN   {E3 REQUESTED}  . ALL SUCH OMITTED MATERIAL  HAS   BEEN   {E4 FILED}  WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO  RULE  24b-2  {E5 PROMULGATED}  UNDER THE SECURITIES EXCHANGE ACT OF  1934 , AS AMENDED

Manufacturing Agreement

Between

Antares Pharma, Inc. and

AMAG Pharmaceuticals, Inc. [***] INDICATES MATERIAL THAT  HAS   BEEN   {E6 OMITTED}  AND FOR WHICH CONFIDENTIAL TREATMENT  HAS   BEEN   {E7 REQUESTED}  . ALL SUCH OMITTED MATERIAL  HAS   BEEN   {E8 FILED}  WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO  RULE  24b-2  {E9 PROMULGATED}  UNDER THE SECURITIES EXCHANGE ACT OF  1934 , AS AMENDED

MANUFACTURING AGREEMENT

This Manufacturing Agreement ("Agreement") is  {E10 made}  and  {E11 entered}  into as of the 20th  day  of  March ,  2018  (the "Effective  Date  ") by and between Antares Pharma, Inc., a Delaware corporation, with offices  located  at 100 Princeton South, Suite 300, Ewing, NJ 08628 ("Antares"), and AMAG Pharmaceuticals, Inc., a Delaware corporation, with a corporate address at 1100 Winter Street, Waltham, MA 02451 ("AMAG"). Antares and AMAG are sometimes  {E12 referred}  to herein individually as a "Party" and collectively as the "Parties". Recitals WHEREAS, AMAG is  {E13 engaged}  in  discovering  ,  developing  and marketing pharmaceutical products,  including  the Drug (as  {E14 defined}  below); WHEREAS, Antares is  {E15 engaged}  in the research and development of certain drug delivery devices,  including  auto-injection systems and the development and marketing of pharmaceutical products; WHEREAS, AMAG Pharma USA, Inc. (f/k/a Lumara Health, Inc., ("AMAG USA")), which was  {E16 acquired}  by AMAG on  November 12, 2014  and is a wholly- owned  subsidiary of AMAG, and Antares  {E17 entered}  into a certain Development and License Agreement ( {E18 defined}  below) under which Antares  {E19 granted}  AMAG USA an exclusive, worldwide license to Antares' VIBEXÂ® QuickShotÂ® (QS) auto-injection system or similar Device ( {E20 defined}  below) for use with the Drug, and further under which Antares and AMAG USA  {E21 agreed}  to  {E22 collaborate}  to  {E23 develop}  such a product;

WHEREAS, contemporaneously with the execution of this Agreement, Antares, AMAG and AMAG USA are  entering  into a First Amendment to Development and License Agreement, pursuant to which, among other amendments set forth therein, AMAG USA  {E24 assigned}  , and AMAG  {E25 assumed}  , the rights and responsibilities under the Development and License Agreement (the "First Amendment to Development and License Agreement");

WHEREAS, AMAG (as the  {E26 permitted}  assignee of the Development and License Agreement) and Antares  {E27 agreed}  under the Development and License Agreement to  {E28 enter}  into this Agreement and, whereby it will  {E29 provide}  Antares or its Subcontractor ( defined  below) with Prefilled Syringes ( defined  below)  containing  the Drug and Antares or it Subcontractor will  {E30 incorporate}  the Prefilled Syringes into Devices to  {E31 produce}   {E32 finished}  Products ( defined  below) and  sample  Products to  {E33 supply}  AMAG's requirements for such Products and sample Products; and

WHEREAS, AMAG  {E34 wishes}  to  {E35 purchase}  , and Antares  {E36 wishes}  to  {E33 supply}  , AMAG's requirements of the Trainers ( defined  below) on the terms set forth in this Agreement. NOW, THEREFORE, in consideration of the foregoing and the mutual covenants and promises  {E38 contained}  in this Agreement, the Parties hereto  {E39 agree}  as  follows  :

- 1 -

[***] INDICATES MATERIAL THAT  HAS   BEEN   {E40 OMITTED}  AND FOR WHICH CONFIDENTIAL TREATMENT  HAS   BEEN   {E41 REQUESTED}  . ALL SUCH OMITTED MATERIAL  HAS   BEEN   {E42 FILED}  WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO  {E43 RULE}  24b-2  {E44 PROMULGATED}  UNDER THE SECURITIES EXCHANGE ACT OF  1934 , AS AMENDED

ARTICLE 1 INTERPRETATION

1.1 Definitions. Capitalized terms  {E45 used}  in this Agreement and not otherwise  {E46 defined}  in this Section 1.1 shall have the meanings set out in the Development and License Agreement. The  following  terms shall, unless the context otherwise  {E47 requires}  , have the respective meanings set out below and grammatical variations of such terms shall have corresponding meanings:

"[***]" has the meaning specified in Section 3.2(c);

"[***]" has the meaning specified in Section 3.2(c);

[***]

"Agreement" has the meaning specified in the Preamble;

"AMAG" has the meaning specified in the Preamble;

"AMAG Indemnitees" has the meaning specified in Section 9.2;

"AMAG USA" has the meaning specified in the Recitals;

"AMAG Quality Tasks" means AMAG's quality, testing and release obligations set forth in Section 2.6(b) and in the Quality Agreement;

"Annual Product Review Report" means the  annual  product review report as described in Title 21 of the United States Code of Federal Regulations, Section 211.180(e);

"Annual Report" means the  annual  report as described in Title 21 of the United States Code of Federal Regulations, Section 314.81(b)(2);

"Antares" has the meaning specified in the Preamble;

"Antares' Fully  {E48 Burdened}  Manufacturing Costs" means those costs actually incurred by Antares related directly to the acquisition of materials and their conversion into Products, sample Products or Trainers, as the case may be. [***];

"Antares Indemnitees" has the meaning specified in Section 9.1;

"Batch Record" means a detailed, step-by-step description of the entire assembly, packaging and labelling process for the Products and sample Products which explains how such Products or sample Products (as the case may be) were assembled, packaged and labelled, indicating specific types and quantities of Components, additional materials, processing parameters, in- process quality controls, and other relevant controls;

- 2 -

[***] INDICATES MATERIAL THAT  HAS   BEEN   {E49 OMITTED}  AND FOR WHICH CONFIDENTIAL TREATMENT  HAS   BEEN   {E50 REQUESTED}  . ALL SUCH OMITTED MATERIAL  HAS   BEEN   {E51 FILED}  WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO  RULE  24b-2  {E52 PROMULGATED}  UNDER THE SECURITIES EXCHANGE ACT OF  1934 , AS AMENDED

"Binding Forecast" has the meaning specified in Section 3.2(a);

"[***]" has the meaning specified in Section 3.2(c);

"Business Day" means  a day  other than a  Saturday ,  Sunday  or  a day  that is a federal holiday in the United States;

"Calendar Quarter" means  a three-  ending on  month  period March 31 ,  June 30 ,  September 30  or  December 31 ;

"Calendar Year" means a calendar  year  occurring after the Effective  Date  ; provided, however, the first Calendar Year means the period from the Effective  Date  up to and including  December 31  of the same calendar  year  in which the Effective  Date  occurs;

"[***]" has the meaning specified in Section 3.2(c);

"Certificate of Analysis (Device)" means a document signed by an authorized representative of Antares or the Subcontractor that conducted the applicable analysis, in reasonable and customary form, that: (i) describes the specifications for, and testing methods applied to, the quantity of each of the Major Device Components manufactured by or on behalf of Antares pursuant to this Agreement, and the results of such testing, and (ii) certifies that such quantity of each of the Major Device Components was manufactured in accordance with cGMP, all other Applicable Laws, and the Product Specifications;

"Certificate of Analysis (PFS Manufacture)" means a document signed by an authorized representative of AMAG, its agent or its permitted subcontractor that conducted the applicable analysis, in reasonable and customary form, that: (i) describes the specifications for, and testing methods applied to the Drug manufactured by or on behalf of AMAG pursuant to this Agreement, and the results of such testing, and (ii) certifies that such quantity of Drug was manufactured in accordance with cGMP, all other Applicable Laws, and the Product Specifications;

"Certificate of Analysis (PFS ID Testing)" means a document signed by an authorized representative of AMAG, its agent or its permitted subcontractor that conducted the applicable analysis, in reasonable and customary form, that describes the specifications for, and testing methods applied to, the Drug manufactured by or on behalf of AMAG pursuant to this Agreement for identification of the Drug, and the results of such testing;

"Certificate of Analysis (Product)" means a document signed by an authorized representative of AMAG, its agent or its permitted subcontractor that conducted the applicable analysis, in reasonable and customary form, that: (i) describes the specifications for, and testing methods applied to, the quantity of Product and/or sample Product manufactured by or on behalf of Antares pursuant to this Agreement, and the results of such testing, and (ii) certifies that such quantity of Product and/or sample Product was

- 3 -

[***] INDICATES MATERIAL THAT  HAS   BEEN   {E53 OMITTED}  AND FOR WHICH CONFIDENTIAL TREATMENT  HAS   BEEN   {E54 REQUESTED}  . ALL SUCH OMITTED MATERIAL  HAS   BEEN   {E55 FILED}  WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO  RULE  24b-2  {E1 PROMULGATED}  UNDER THE SECURITIES EXCHANGE ACT OF  1934 , AS AMENDED

{E56 manufactured}  in accordance with cGMP, all other Applicable Laws, and the Product Specifications;

"Certificate of Conformance (Device)" means the document provided to AMAG by Antares or the Subcontractor that conducted the applicable review, as the case may be, that certifies each batch of each of the Major Device Components was manufactured in compliance with the cGMP, all other Applicable Laws, and the Product Specifications;

"Certificate of Conformance (Product)" means the document provided to AMAG by Antares or the Subcontractor that conducted the applicable review, as the case may be, that certifies each batch of Product and/or sample Product was assembled, packaged and labelled in compliance with the cGMP, all other Applicable Laws, and the Product Specifications;

"cGMP" means  current  good manufacturing practice and standards as provided for (and as amended from time to time) in the " Current  Good Manufacturing Practice Regulations" of the U.S. Code of Federal Regulations Title 21 (21CFRÂ§4; 21CFRÂ§210/211 and 21CFRÂ§820) and in European Community Council Directive 93/42/EEC concerning medical devices, any U.S., European, or other applicable laws, regulations or respective guidance documents  now  or subsequently established by a governmental or regulatory authority, and any arrangements, additions, or clarifications;

" Change  Order" has the meaning specified in Section 4.2(b);

"Commercially Reasonable Efforts" means, with respect to each Party, such efforts and commitment of resources in accordance with [***] that such Party [***]. As  {E57 used}  in this definition of "Commercially Reasonable Efforts", "reasonable" shall be  {E58 measured}  by [***]. References in this Agreement to "commercially reasonable" and similar formulations shall be  deemed  to  {E59 incorporate}  the standard set forth in this definition of "Commercially Reasonable Efforts";

"Components" means, collectively, [***];

"Damages" has the meaning specified in Section 9.1;

"Deficiency Notice" has the meaning specified in Section 5.1(a);

"Delivery  Date  " means the delivery date of a Purchase Order of Products, sample Products or Trainers as agreed upon by the Parties pursuant to Section 3.2(b)(i) or Antares' proposed date if AMAG does not respond within the [***] set forth in Section 3.2(b)(i);

"Development and License Agreement" means that certain Development and License Agreement entered into by and between the Parties dated as of  September 30, 2014 , as amended by the First Amendment to the Development and License Agreement, and as further amended by the Parties from time to time;

- 4 -

[***] INDICATES MATERIAL THAT  HAS   BEEN   {E60 OMITTED}  AND FOR WHICH CONFIDENTIAL TREATMENT  HAS   BEEN   {E61 REQUESTED}  . ALL SUCH OMITTED MATERIAL  HAS   BEEN   {E62 FILED}  WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO  {E63 RULE}  24b-2  {E64 PROMULGATED}  UNDER THE SECURITIES EXCHANGE ACT OF  1934 , AS AMENDED

"Device" means the VIBEXÂ® QS auto-injection system device, consisting of the Major Device Components, designed and developed to incorporate a Prefilled Syringe for delivery of the Drug, and any improvements or modifications thereof made pursuant to the Development and License Agreement, or such other Antares-proprietary device as agreed to by Antares designed and developed to deliver the Drug pursuant to the Development and License Agreement, as further set forth on Exhibit B. For greater certainty, the Major Device Components are intended to be assembled with the Prefilled Syringe to produce a finished Product;

"DHF" has the meaning specified in the Development and License Agreement;

"DMF" has the meaning specified in the Development and License Agreement and is expanded to further clarify that a DMF is equivalent to an "MAF" or Master File;

"Drug" means 17-alpha hydroxyprogesterone caproate;

"Effective  Date  " has the meaning specified in the Preamble;

[***]

"Excess Order" has the meaning specified in Section 3.2(b)(i);

"Firm Orders" means any Purchase Order accepted by Antares pursuant to Section 3.2(b)(i) (as evidenced by an Order Acceptance), including any Excess Orders agreed to by Antares in an Order Acceptance, with the Delivery  Date  as set forth in Section 3.2(b)(i);

"First Amendment to the Development and License Agreement" has the meaning specified in the Recitals;

"Force Majeure Event" has the meaning specified in Section 12.4;

"Forecast" has the meaning specified in Section 3.2(a);

"[***]" has the meaning specified in Section 4.6;

"[***]" has the meaning specified in Section 3.2(c);

"[***]" has the meaning specified in Section 3.2(c);

"Invoice" has the meaning specified in Section 4.2(a);

"[***]" has the meaning specified in Section 3.2(c);

"Latent Defects" has the meaning specified in Section 5.1(a);

- 5 -

[***] INDICATES MATERIAL THAT  HAS   BEEN   {E65 OMITTED}  AND FOR WHICH CONFIDENTIAL TREATMENT  HAS   BEEN   {E66 REQUESTED}  . ALL SUCH OMITTED MATERIAL  HAS   BEEN   {E67 FILED}  WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO  RULE  24b-2  {E68 PROMULGATED}  UNDER THE SECURITIES EXCHANGE ACT OF  1934 , AS AMENDED

"Long Lead Time Materials" means [***], a description of which are set forth on Exhibit A (as such exhibit may be amended from time to time by the mutual written agreement of the Parties), [***];

"Major Device Components" means the following Components of the Device: [***]. "Manufacture(d) at Risk" has the meaning specified in Section 3.7(a);

"Manufacturing Services" means the manufacturing, quality control and quality assurance, storage, labelling, packaging, assembly and related services, to be performed by Antares or its Subcontractor as contemplated in this Agreement and described in the Specifications and the Quality Agreement, required to manufacture Devices and produce and supply Trainers, Products and sample Products from such Devices, Prefilled Syringes and Components. For the avoidance of doubt, the "Manufacturing Services" specifically  {E69 excludes}  the AMAG Quality Tasks and all other services, activities or tasks to be  {E70 performed}  by or on behalf of AMAG set forth in this Agreement or as otherwise  {E71 described}  in the Specifications or the Quality Agreement;

"Manufacturing Site" means [***] or such other facility owned and operated by Antares or a Subcontractor on behalf of Antares under this Agreement [***]. "Non-Binding Forecast" has the meaning specified in Section 3.2(a);

"Non-Cancellable Non-Returnable Materials" or "NCNR Materials" means [***];

[***]

"Order Acceptance" has the meaning specified in Section 3.2(b)(i);

"Other Approved Antares Product" has the meaning specified in Section 4.6(a);

"Parties" and "Party" have the meanings  {E72 specified}  in the Preamble;

"Person" means any natural person, a corporation, a partnership, a trust, a joint venture, a limited liability company, any Governmental Authority or any other entity or organization;

"[***]" has the meaning specified in Section 2.1(b);

"Prefilled Syringe" means the prefilled syringe containing the formulated Drug for incorporation into the Device, as further set forth in the Product Specifications;

"Prior Orders" has the meaning specified in Section 3.2(c);

"Product(s)" means the fully packaged Device for auto-injection delivery of the Drug incorporating a Prefilled Syringe and other applicable Components listed on Exhibit B

- 6 -

[***] INDICATES MATERIAL THAT  HAS   BEEN   {E73 OMITTED}  AND FOR WHICH CONFIDENTIAL TREATMENT  HAS   BEEN   {E74 REQUESTED}  .



#COLOR:E33=hsl(0, 100%, 80%)

#TOKENIZATION-TYPE:1

